CEA is recommended by the NACB (National Academy of Clinical Biochemistry) guidelines for NSCLC diagnosis when combined with CYFRA21-1, and IDH1 is used as a blood biomarker for the diagnosis of NSCLC65. The gene discussed is BTF3; the disease is non-small cell lung carcinoma.